| CAS: | 1805787-93-2 | |
| 分子式: | C26H30ClN7O2 | |
| 分子量: | 508.02 | |
| 英文名称: |
| |
| 用途: | JAK3-IN-1是一种有效的JAK3抑制剂, IC50值为4.8 nM, 也能抑制JAK1 (IC50 =896nM) 和JAK2 (IC50 =1050nM)。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||
| J881214 | MACKLIN | JAK3-IN-1 | ≥99% | 2801元/5mg; 4001元/10mg; | 咨询 | ||
储存:2-8℃ | |||||||
| HY-19544 | MCE | JAK3-IN-1,1805787-93-2_MCE(MedChemExpress) | 3129元/10 mM * 1 mL in DMSO; 2800元/5 mg; 4000元/10 mg; | 咨询 | |||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 JAK3-IN-1MCE 国际站:JAK3-IN-1 品牌:MedChemExpress (MCE) 货号:HY-19544 CAS 号:1805787-93-2 生物活性:JAK3-IN-1 是一种强效、选择性强且口服有效的 JAK3 抑制剂,IC50 为 4.8 nM。JAK3-IN-1 对 JAK3 的选择性比 JAK1(IC50 为 896 nM)和 JAK2(IC50 为 1050 nM)高 180 倍以上[1]。 体外研究(In Vitro):JAK3-IN-1(Compound 9; 0-5 µM; 3 hours; BMDMs cells) treatment completely inhibits IL-4 induced p-STAT6 at a concentration of 500 nM and only partially inhibits IFNβ-induced p-STAT1 at a concentration of 5.0 μM[1].. JAK3-IN-1(Compound 9) most potently inhibits JAK3 and identified fms-related tyrosine kinase 3 (FLT3) and several tyrosine protein kinase (TEC)-family kinases as being potential off-targets. Enzymatic assays using the Z’-lyte or LanthaScreen formats confirmed enzymatic inhibition of FLT3 (IC50 = 13 nM), TTK protein kinase (TTK, IC50 = 49 nM), BLK proto-oncogene (BLK, IC50 = 157 nM) and tyrosine protein kinase TXK (TXK, IC50 = 36 nM). JAK3-IN-1 shows very low inhibition scores for other JAKs and wild-type (WT) EGFR, which is consistent with the over 180-fold higher IC50s against EGFRWT and TYK2 (IC50s =409 nM, > 10000 respectively). JAK3-IN-1 possesses over 165-fold higher IC50s for BTK or ITK (IC50s = 794 and 1070 nM respectively)[1]. JAK3-IN-1(Compound 9) selectively inhibits the proliferation of JAK3-dependent Ba/F3 cells (IC50 = 69 nM) relative to other JAK-dependent Ba/F3 cells, for which there was no antiproliferative effect at concentrations below 3.0 μM[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。 体内研究(In Vivo):JAK3-IN-1(Compound 9) shows reasonable pharmacokinetic properties, with moderate T1/2 of 1.4 h, area under the curve (AUC) value of 795 ng*hr/mL following a 10 mg/Kg oral dose and good oral bioavailability of 66%. After oral administration with JAK3-IN-1(Compound 9) (75 mpk, QD) for 8 days, the numbers of B or T lymphocytes in the tumor-bearing lungs and spleens of treated mice is not affected, however, the number of NK cells is reduced[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。 分子量:508.02 Formula:C26H30ClN7O2 性状:固体 颜色:White to off-white 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式:粉末 -20°C 3年 提供质量检测报告:Data Sheet、SDS、COA、LCMS、产品使用指南 产品活性:JAK3-IN-1 是一种有效,选择性和口服活性的 JAK3 抑制剂,IC50 为 4.8 nM。与 JAK1 (IC50 为 896 nM) 和 JAK 2 (IC50 为 1050 nM) 相比,JAK3-IN-1 对 JAK3 的选择性高 180 倍以上。 IC50 & Target:JAK3 4.8 nM (IC50) 相关产品:CHZ868 | Upadacitinib | Upadacitinib (Standard) | Filgotinib (Standard) | Filgotinib | Peficitinib | Phytohemagglutinin | JAK-IN-35 | AMG-47a | BMS-066 | RO495 | S6K1-IN-1 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 参考文献: 品牌介绍:
| |||||||